Emphasizing enhanced time-of-flight performance and an energy-efficient design, the Biograph Trinion PET/CT system can reportedly be utilized for a variety of imaging needs, ranging from theranostic applications to neurology imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Biograph Trinion positron emission tomography/computed tomography (PET/CT) system, which made its debut at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, including oncologic, cardiovascular, and neurologic imaging as well as theranostics, according to Siemens Healthineers, the manufacturer of the Biograph Trinion.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, according to Siemens Healthineers, the manufacturer of the newly FDA-cleared PET/CT system. (Image courtesy of Siemens Healthineers.)
The company emphasized that the device’s computer technology is located in the system gantry, allowing a more compact design that can be accommodated in an existing traditional PET/CT room. Siemens Healthineers added that the system’s smart power-save mode for powering down at night, can lead to a 46 percent reduction in energy costs.
“With the Biograph Trinion, Siemens Healthineers is proud to offer customers a high-performance PET/CT scanner that delivers the precision and speed needed for clinical demands,” said James Williams, PhD, head of Molecular Imaging at Siemens Healthineers. “This new system is designed to be user- and patient focused as well as a sustainable investment in terms of reduced installation and operational costs and easy, on-site scalability.”
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.